206 related articles for article (PubMed ID: 35155243)
1. Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer.
Principe DR; Underwood PW; Kumar S; Timbers KE; Koch RM; Trevino JG; Munshi HG; Rana A
Front Oncol; 2022; 12():806963. PubMed ID: 35155243
[TBL] [Abstract][Full Text] [Related]
2. TGFβ Antagonizes IFNγ-Mediated Adaptive Immune Evasion via Activation of the AKT-Smad3-SHP1 Axis in Lung Adenocarcinoma.
Ye F; Cai Z; Wang B; Zeng C; Xi Y; Hu S; Qu R; Yuan Z; Yue J; Tian Y; Wang X; Fu X; Li L
Cancer Res; 2023 Jul; 83(13):2262-2277. PubMed ID: 37145144
[TBL] [Abstract][Full Text] [Related]
3. TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell-Mediated Regression of Pancreatic Cancer.
Principe DR; Park A; Dorman MJ; Kumar S; Viswakarma N; Rubin J; Torres C; McKinney R; Munshi HG; Grippo PJ; Rana A
Mol Cancer Ther; 2019 Mar; 18(3):613-620. PubMed ID: 30587556
[TBL] [Abstract][Full Text] [Related]
4. Hepatic myofibroblasts exert immunosuppressive effects independent of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic ductal adenocarcinoma.
Beckinger S; Daunke T; Aldag L; Krüger S; Heckl S; Wesch D; Schäfer H; Röcken C; Rahn S; Sebens S
Front Oncol; 2023; 13():1160824. PubMed ID: 37207152
[TBL] [Abstract][Full Text] [Related]
5. TGF-β Alters the Proportion of Infiltrating Immune Cells in a Pancreatic Ductal Adenocarcinoma.
Trebska-McGowan K; Chaib M; Alvarez MA; Kansal R; Pingili AK; Shibata D; Makowski L; Glazer ES
J Gastrointest Surg; 2022 Jan; 26(1):113-121. PubMed ID: 34260016
[TBL] [Abstract][Full Text] [Related]
6. TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer.
Perez-Penco M; Weis-Banke SE; Schina A; Siersbæk M; Hübbe ML; Jørgensen MA; Lecoq I; Lara de la Torre L; Bendtsen SK; Martinenaite E; Holmström MO; Madsen DH; Donia M; Ødum N; Grøntved L; Andersen MH
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600556
[TBL] [Abstract][Full Text] [Related]
7. Smad4 Deficiency Promotes Pancreatic Cancer Immunogenicity by Activating the Cancer-Autonomous DNA-Sensing Signaling Axis.
Xiong W; He W; Wang T; He S; Xu F; Wang Z; Wang X; Guo H; Ling J; Zhang H; Liu Y; Xing K; Li M; Zhang H; Li J; Niu N; Xue J; Zhan Q; Liu ZX; Bei JX; Huang P; Liu J; Xia L; Xia X
Adv Sci (Weinh); 2022 Mar; 9(7):e2103029. PubMed ID: 35064757
[TBL] [Abstract][Full Text] [Related]
8. Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1.
Radke DI; Ungefroren H; Helm O; Voigt S; Alp G; Braun H; Hübner S; Dilchert J; Sebens S; Adam D; Kalthoff H; Trauzold A
Cell Signal; 2016 Nov; 28(11):1652-62. PubMed ID: 27492861
[TBL] [Abstract][Full Text] [Related]
9. Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression.
Zheng NN; Zhou M; Sun F; Huai MX; Zhang Y; Qu CY; Shen F; Xu LM
World J Gastroenterol; 2020 Jul; 26(26):3737-3749. PubMed ID: 32774054
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.
Wang X; Li X; Wei X; Jiang H; Lan C; Yang S; Wang H; Yang Y; Tian C; Xu Z; Zhang J; Hao J; Ren H
Signal Transduct Target Ther; 2020 Apr; 5(1):38. PubMed ID: 32300119
[TBL] [Abstract][Full Text] [Related]
11. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
12. Thrombospondin-1 overexpression stimulates loss of Smad4 and accelerates malignant behavior via TGF-β signal activation in pancreatic ductal adenocarcinoma.
Matsumura K; Hayashi H; Uemura N; Ogata Y; Zhao L; Sato H; Shiraishi Y; Kuroki H; Kitamura F; Kaida T; Higashi T; Nakagawa S; Mima K; Imai K; Yamashita YI; Baba H
Transl Oncol; 2022 Dec; 26():101533. PubMed ID: 36115074
[TBL] [Abstract][Full Text] [Related]
13. Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Golesworthy B; Wang Y; Tanti A; Pacis A; Romero JM; Cuggia A; Domecq C; Bourdel G; Denroche RE; Jang GH; Grant RC; Borgida A; Grünwald BT; Dodd A; Wilson JM; Bourque G; O'Kane GM; Fischer SE; Kron CM; Fiset PO; Omeroglu A; Foulkes WD; Gallinger S; Guiot MC; Gao ZH; Zogopoulos G
Front Oncol; 2022; 12():860767. PubMed ID: 35547873
[TBL] [Abstract][Full Text] [Related]
14. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients.
Hiraoka N; Ino Y; Hori S; Yamazaki-Itoh R; Naito C; Shimasaki M; Esaki M; Nara S; Kishi Y; Shimada K; Nakamura N; Torigoe T; Heike Y
Cancer Sci; 2020 Aug; 111(8):3057-3070. PubMed ID: 32495519
[TBL] [Abstract][Full Text] [Related]
15. SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells.
Chen YW; Hsiao PJ; Weng CC; Kuo KK; Kuo TL; Wu DC; Hung WC; Cheng KH
BMC Cancer; 2014 Mar; 14():181. PubMed ID: 24625091
[TBL] [Abstract][Full Text] [Related]
16. TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.
Malinda RR; Zeeberg K; Sharku PC; Ludwig MQ; Pedersen LB; Christensen ST; Pedersen SF
Front Oncol; 2020; 10():687. PubMed ID: 32457840
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis.
Tsukamoto M; Imai K; Ishimoto T; Komohara Y; Yamashita YI; Nakagawa S; Umezaki N; Yamao T; Kitano Y; Miyata T; Arima K; Okabe H; Baba Y; Chikamoto A; Ishiko T; Hirota M; Baba H
Cancer Sci; 2019 Jan; 110(1):310-320. PubMed ID: 30426611
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8
Yamaki S; Yanagimoto H; Tsuta K; Ryota H; Kon M
Int J Clin Oncol; 2017 Aug; 22(4):726-733. PubMed ID: 28314962
[TBL] [Abstract][Full Text] [Related]
19. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis.
Gao HL; Liu L; Qi ZH; Xu HX; Wang WQ; Wu CT; Zhang SR; Xu JZ; Ni QX; Yu XJ
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):95-100. PubMed ID: 29576277
[TBL] [Abstract][Full Text] [Related]
20. Comparison of programmed death ligand 1 immunostaining for pancreatic ductal adenocarcinoma between paired cytological and surgical samples.
Muggilli M; Russell D; Zhou Z
Cytojournal; 2021; 18():28. PubMed ID: 34876919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
